Heinz Stadtmueller

Title: Heinz Stadtmueller: Innovator in Cancer Treatment

Introduction

Heinz Stadtmueller is a notable inventor based in Munich, Germany. He has made significant contributions to the field of oncology through his innovative research and development of pharmaceutical compounds. With a total of two patents to his name, Stadtmueller's work focuses on the treatment and prevention of oncological diseases.

Latest Patents

Stadtmueller's latest patents include "Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors." This invention encompasses compounds of formula (I), wherein the groups Rto R and Xto X have the meanings given in the claims and specification. These compounds are utilized as inhibitors of mutant EGFR and are included in pharmaceutical compositions for medical uses, particularly in treating oncological diseases. Another significant patent is "Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer," which also focuses on compounds of formula (I) aimed at combating cancer.

Career Highlights

Throughout his career, Stadtmueller has worked with prominent organizations, including Boehringer Ingelheim International GmbH and Vanderbilt University. His experience in these institutions has allowed him to advance his research and contribute to the development of effective cancer treatments.

Collaborations

Stadtmueller has collaborated with notable colleagues such as Juergen Ramharter and Tobias Wunberg. These partnerships have played a crucial role in enhancing his research and expanding the impact of his inventions.

Conclusion

Heinz Stadtmueller is a distinguished inventor whose work in cancer treatment has the potential to make a significant difference in the medical field. His innovative patents and collaborations reflect his commitment to advancing healthcare solutions.